arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

GILEAD SCIENCES, INC.

GILD
$133.13 ▲ +2.28 (+1.74%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
74 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
80
Health
Excellent
Bullish
auto_awesome

Analytical Summary

GILEAD SCIENCES, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $165.3B
Dividend Yield 0.62%
Revenue Growth 4.4%
Op. Margin 37.2%
ROIC 4.4%
FCF / Share $1.95
Trailing P/E 81.7x
Price / Book 7.0x
FCF Yield 1.5%
Debt / Equity 0.94
info Valuation on last close. End-of-day price, Aug 7, 2026.

74-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$6.96B
↑ +4.4%
Net Income Profit after all expenses
$2.02B
↑ +53.7%
Operating Margin Operating profit as % of sales
37.2%
↑ +48.4% 90th
FCF / Share Free cash flow per share
$1.95
↑ +47.3%
Long-Term Debt Long-term obligations
$22.17B
↓ -11.1%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
91
Returns
95
Financial Health
54
Cash Quality
70

Dividend History

Dividend / share · sourced from SEC filings
$3.16 Latest / share
+2.6% YoY

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 20 years · 74 quarters